The Filing Desk

Kamada vs Phathom Pharmaceuticals

Kamada KMDA · Phathom Pharmaceuticals PHAT · Pharmaceuticals

Kamada reported revenue of $180 million in fiscal 2025, about the same as Phathom Pharmaceuticals' $175 million in fiscal 2025. Kamada's revenue grew 12.1% in its latest year, and Phathom Pharmaceuticals' grew 216.9%. Kamada had an operating margin of 14.5%, against -91.4% at Phathom Pharmaceuticals. Free cash flow was $16 million at Kamada and −$167 million at Phathom Pharmaceuticals.

Side by side

KamadaPhathom Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$180M$175M
Revenue growth12.1%216.9%
Revenue growth a year, last 5 years6.3%—
Gross margin42.3%87.1%
Operating margin14.5%−91.4%
Net margin11.2%−126.3%
Free cash flow$16M−$167M
Free cash flow margin8.7%−95.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$12M$0M
Change in diluted share count0.9%15.4%
Last close$7.83$5.08
P/E at the last close——
Insider trades, last 12 monthssold $1.7 million—
Piotroski F-score—4 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
KamadaPhathom Pharmaceuticals
Operating margin
Percent of revenue
KamadaPhathom Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
KamadaPhathom Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kamada and Phathom Pharmaceuticals pages.